JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on May 12, 2004; DOI: 10.1124/jpet.104.069146


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.104.069146v1
311/1/220    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Williams, A. J
Right arrow Articles by Hartings, J. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Williams, A. J
Right arrow Articles by Hartings, J. A


Received for publication April 6, 2004.
Revised April 30, 2004.
Accepted for publication May 12, 2004.

Anti-Epileptic Drug Treatment of Non-Convulsive Seizures Induced by Experimental Focal Brain Ischemia

Anthony J Williams 1*, Frank C Tortella 1, Xi-Chun M Lu 1, J Edward Moreton 2, Jed A Hartings 1

1 Walter Reed Army Institute of Research 2 University of Maryland

* Address correspondence to: E-mail: anthony.williams{at}na.amedd.army.mil

Abstract

Non-convulsive seizures (NCS) following traumatic and ischemic brain injury are often refractory to anti-epileptic drug (AED) therapy and are associated with a decline in patient outcome. We recently characterized an in vivo rat model of focal brain ischemia-induced NCS and here sought to evaluate potential pharmacological AED treatments. Electroencephalographic (EEG) activity was recorded continuously for 24 h in freely behaving rats subjected to permanent middle cerebral artery occlusion (MCAo). Rats were treated with AEDs from one of seven different drug classes at ED50 and 2X ED50 doses (as reported in other rat seizure models), delivered as a single i.v. injection 20 min post-MCAo. Vehicle treated rats (n = 9) had an 89% incidence of NCS with an average number of NCS = 8.6 ± 1.9. The latency to onset of NCS was 32.5 ± 3.4 min post-MCAo with and average duration = 49.1 ± 8.2 s per event. The high dose of ethosuximide (EXM), gabapentin (GBP), fos-phenytoin (FPT), and valproate (VPA) significantly reduced the incidence of NCS (11%, 14%, 14%, and 38%, respectively), whereas midazolam (MDZ), phenobarbital (PHB), and dextromethorphan (DM) had no significant effect at either dose. Across treatment groups, the number of NCS events per animal was positively correlated with brain infarction (r = 0.352. p<0.05). AED therapy that prevented the occurrence of NCS also reduced mortality from 26% to 7%. Based on combined effects on NCS, infarction, neurologic recovery, and mortality, EXM and GBP were identified as having the best therapeutic profile.


Key words: MCAO, anti-epileptic drug, brain injury, brain ischemia, seizure, stroke


This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
A. J. Williams, C. C. Bautista, R.-W. Chen, J. R. Dave, X.-C. M. Lu, F. C. Tortella, and J. A. Hartings
Evaluation of Gabapentin and Ethosuximide for Treatment of Acute Nonconvulsive Seizures following Ischemic Brain Injury in Rats
J. Pharmacol. Exp. Ther., September 1, 2006; 318(3): 947 - 955.
[Abstract] [Full Text] [PDF]


Home page
Alcohol AlcoholHome page
H. C. BECKER, H. MYRICK, and L. M. VEATCH
PREGABALIN IS EFFECTIVE AGAINST BEHAVIORAL AND ELECTROGRAPHIC SEIZURES DURING ALCOHOL WITHDRAWAL
Alcohol Alcohol., July 1, 2006; 41(4): 399 - 406.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.